	2-pyr EHDP	15.742316286160921
¡°	compound risedronate	9.93970540257676
¡°	market risedronate	9.882561597836753
¡°	risedronate potency	6.644736082864679
¡°	risedronate inventor	6.5876506162402295
	Risedronate	3.1726334102763136
	different bisphosphonate compound	1.3097980467345622
¡°	p G osteoporosis drug Actonel	1.30894028252836
	Geminal Diphosphonates	1.1910387470995765
	bone mineralization	1.18807221529171
	bone resorption	1.0320298626652424
	first two promising bisphosphonate	0.8530347892913284
	PharmaStem Therapeutics	0.7205346317083267
	ViaCell	0.6384571607154873
	anti mineralization	0.5517708115602286
	anti resorption	0.44774257647591686
	Takeda	0.4275853274189787
	metabolic bone disease	0.40605778921789
	Light	0.31937831235919667
	treat Osteoporosis	0.23033645840234895
	intermittent dosing method	0.21730675291578994
	cyclic administrative regiman	0.20052142151098856
	Ugine	0.19245896444113933
	Soni	0.19245896444113933
	thirty six polyphosphonate molecule	0.17658660173530855
	promising drug candidate	0.16146417299493088
	Lead Compound	0.1591140633981859
	benign effect	0.15284620853946532
	toxicity	0.15110711400575683
	satisfaction	0.13430158005493498
	researcher	0.13275610355637232
	promising molecule	0.1288206439920183
	non statutory double patenting	0.09585164960870132
	Golden Blount	0.0902051769147413
	treatment candidate	0.08047440134190881
	obviousness obviousness type double patenting	0.06787221539422036
	designation	0.06750902135682937
	Georgia Pacific Corp.	0.06630453390819444
	assignment	0.06008703093156534
	DISCUSSION	0.04881993945938216
	invalidity defense	0.04752935767093813
	chemical compound	0.044234463397859934
	consolidated appeal	0.04420304561842119
	eight preferred compound	0.04325402537300038
	commercialization	0.04283871760180508
	unwanted side effect	0.03972161328955893
	lead compound	0.039223647985182485
	know compound	0.038828412211607516
	prior art compound	0.038825697273799926
	helpful insight	0.03869977726634097
	hundred	0.03685254576437418
	Pfizer	0.0337703430028146
	Labs. Ltd.	0.03376287960081202
	prima facie case	0.0317473194181755
	experimentation	0.031631157657635633
	specific molecular modification	0.03126415023081314
	Obviousness Legal Standard	0.031191143760787736
	structural similarity	0.03046893856469829
	extremely unpredictable nature	0.026624155263054457
	Delaware	0.025918114367758094
	unexpected result	0.02372897188116706
	superior property	0.018313357872549348
	Jr.	0.016947868185351357
	Apotex	0.01680828886818098
	reasonable expectation	0.016789177094056872
	I. Standard	0.016315642943514515
	reason identification	0.016264490697611645
	IV	0.015822997018848053
	post KSR	0.015762025989538905
	Mylan Labs.	0.015440103092441456
	Prior Art	0.015353199259377495
	Review	0.0129651355417971
	active ingredient	0.01193684550008991
	clinical problem	0.011487029016276922
	i. BACKGROUND	0.010298613644599561
	challenger	0.009855623316876196
	pharmaceutical composition	0.009096439256736895
	secondary consideration	0.007138742884068027
	Opinion	0.007057384393734168
	patient	0.007057384393734168
	long feel need	0.006999205598788386
	commercial success	0.006161205464992109
	quotation mark	0.0061579388557615735
	December	0.003964324501327997
	August	0.0033914659020558885
	fact finder	0.0031597168975995623
	skilled artisan	0.0031099093703525487
	central problem	0.0030946210074020105
	preliminary finding	0.002651596482695435
	Teleflex Inc.	0.002520936823282985
	advantage	0.0022949402749425393
	Chem	0.002181498542149332
	owner	0.002106500395541424
	bench trial	0.001618009753290897
	contest	0.0015914100901170227
	deference	0.0015353826103072217
	evidentiary burden	0.0014690083177948305
	Federal Circuit teaching suggestion motivation test	0.001195279543397399
	generic equivalent	0.0011285541605365373
	June	0.001084989255825799
	II	0.0010311981475738543
	Supreme Court	0.000889501389375389
	Indus	0.0006295409104325147
	pertinent art	0.0005163227153139036
	underlie factual inquiry	0.0005070247317320347
	obviousness determination	0.00033378459347808086
	obviousness argument	0.00033296901039135343
	obviousness question	0.00033280547873134415
	obviousness issue	0.0003327708268787825
	significant amount	0.0003078318355200222
	particular manner	0.0002708746799870002
	relevant factor	0.0002560658280243205
	clear convincing evidence	0.00024070678544428742
	factual contention	0.00018457762668728578
	turn	0.0001804653839528325
	ordinary skill	0.00012685102648429846
	background	7.620967901496027e-05
	level	6.649202577867302e-05
	law de novo	5.3266190851153154e-05
	evidence place	5.088270904244389e-05
	favor	4.326243046796322e-05
	holding	3.916905934738175e-05
	jurisdiction	3.23206781866076e-05
	final judgment	3.195196949663518e-05
	clear error	2.3399505930307262e-05
	legal question	1.7828441695368587e-05
	factual determination	1.7159300242035003e-05
	three case	1.6922115265020596e-05
	trial court	5.649469506217035e-06
	subject matter	3.5588829719647245e-06
	light	2.6152420615956865e-06
	relevant art	1.8116601604090776e-06
	relate case	1.4042960211568488e-06
	district court conclusion	1.2945771172578302e-06
	infringement action	5.808869999206758e-08
	party	4.571853010570081e-08
	prior art reference	4.177779950703249e-08
	invention	5.770940611163239e-09
	District	0.0
	Appeals	0.0
